ViroLogic, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Proposed initial public offering valued at up to $75 mil. is outlined in a preliminary prospectus filed Feb. 22 with the Securities and Exchange Commission. The South San Francisco biotechnology firm's first product, the PhenoSense HIV phenotypic test to directly and quantitatively measure resistance of a patient's HIV to antiviral drugs in order to facilitate appropriate drug selection, commenced active marketing in November 1999 (1"The Gray Sheet" Nov. 22, p. 15). The company is also developing PhenoSense products for other viral diseases, including hepatitis B and C. Proceeds from the IPO will be used to expand sales and marketing activities and for various capital expenditures, including clinical laboratory expansion. CIBC World Markets Corp. is lead manager of the offering; ING Barings and Prudential Vector Healthcare Group are co-managers